Your Messages Inbox
Your Article Summary
See Latest ArticlesShire Secures European Wide Label Extension for FOSRENOL in Chronic Kidney Disease
Shire, 10/29/09
Shire plc, the global specialty biopharmaceutical company, announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL, paving the way to make the non–calcium, non–resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease patients who are not on dialysis with a serum phosphorus level >1.78mmol/L.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Article Search
Sponsor